# GLP-1 Receptor Agonists: Diabetes Risk Despite Weight Loss

> **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637)
> **Publisher:** CED Clinic (https://cedclinic.com)
> **Canonical URL:** https://cedclinic.com/glp-1-receptor-agonist-diabetes-risk/
> **Published:** 2026-06-10T11:30:38-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:05:16-04:00
> **Clinical Summary:** Explore GLP-1 receptor agonist diabetes risk despite weight loss and the importance of metabolic monitoring beyond weight metrics for clinicians.

---

GLP-1 Clinical Relevance  #51Moderate Clinical Relevance  Relevant context for GLP-1 prescribers; interpret with care.
⚕ GLP-1 News  |  CED Clinic
[Clinical Research](https://cedclinic.com/cannabis-based-therapies-smoking-cessation/)Observational StudyType 2 Diabetes PreventionGLP-1 Receptor AgonistEndocrinologyAdults with ObesityGlycemic ControlInsulin ResistanceTULIP Study[Metabolic Health](https://cedclinic.com/cannabis-compounds-reverse-fatty-liver-disease/) AssessmentWeight Loss ParadoxGlucose Deterioration Risk

Why This Matters

Family medicine clinicians prescribing GLP-1 receptor agonists must recognize that weight loss alone does not guarantee improved glycemic control or resolution of insulin resistance in all patients, as demonstrated by the TULIP cohort showing glucose deterioration in a subset despite weight reduction. This finding necessitates continued metabolic monitoring including fasting glucose, HbA1c, and insulin levels independent of weight loss trajectories to identify treatment failures early and adjust therapeutic strategy accordingly. Understanding this metabolic heterogeneity prevents false reassurance from weight reduction metrics and ensures clinically appropriate escalation or combination therapy in patients whose underlying insulin resistance persists.

Clinical Summary
The TULIP study enrolled 190 patients to evaluate metabolic outcomes beyond weight reduction alone. A subset of study participants demonstrated persistent insulin resistance despite achieving weight loss, which correlated with deterioration in blood glucose levels during follow-up. This finding demonstrates that weight loss as a standalone marker does not necessarily reflect improvement in underlying [glucose metabolism](https://cedclinic.com/tetrahydrocannabinol-brain-glucose-consumption-metabolic-modulation/) or insulin sensitivity in all patients.

The clinical implications for prescribers center on the heterogeneity of metabolic response to interventions. Some patients experience metabolic decoupling, where weight reduction occurs without concordant improvement in insulin resistance or fasting glucose levels. This population may progress toward or experience frank hyperglycemia despite meeting weight loss targets, indicating that weight alone should not serve as the primary efficacy endpoint when evaluating diabetes prevention or [metabolic health](https://cedclinic.com/cannabis-compounds-reverse-fatty-liver-disease/) interventions.

For [clinical practice](https://cedclinic.com/cannabis-reproductive-health-women-clinical-evidence/), these findings support the value of monitoring insulin resistance markers and glucose parameters independently from weight metrics. Patients achieving weight loss but demonstrating persistent insulin resistance or worsening glucose control may warrant treatment intensification, additional pharmacologic intervention, or assessment of adherence and lifestyle factors. The data suggest that a subset of patients requires more aggressive metabolic management than weight loss alone provides, with direct measurement of insulin sensitivity and glycemic control essential to identifying those at continued diabetes risk.

Clinical Takeaway

Patients taking GLP-1 medications may achieve significant weight loss while still developing worsening glucose control if underlying insulin resistance remains unaddressed. The TULIP study demonstrates that weight reduction alone does not guarantee metabolic improvement in all patients, particularly those with persistent insulin resistance. This finding suggests the need for comprehensive metabolic assessment beyond weight outcomes, including regular glucose monitoring and insulin sensitivity markers. In [clinical practice](https://cedclinic.com/cannabis-reproductive-health-women-clinical-evidence/), counsel patients that GLP-1 therapy requires concurrent lifestyle optimization and metabolic monitoring to prevent diabetes progression despite apparent weight loss success.

Dr. Caplan’s Take
“What the TULIP study demonstrates is something I see regularly in clinical practice: weight loss alone doesn’t guarantee metabolic recovery in every patient, and we can have individuals who lose significant weight yet continue to worsen their glucose control due to persistent underlying insulin resistance. This finding fundamentally changes how I counsel patients, because I now emphasize that we’re not just treating a number on the scale-we’re treating insulin resistance and beta cell dysfunction, which may require more aggressive pharmacotherapy even when weight loss is occurring. The practical implication for my practice is straightforward: I monitor HbA1c and fasting glucose closely in patients on GLP-1 therapy regardless of their weight loss trajectory, because metabolic improvement must be independently confirmed rather than assumed. For patients, this means the conversation shifts from ‘you need to lose X pounds’ to ‘we need to restore your metabolic health,’ which actually improves adherence and reduces shame.”

Clinical Perspective
🧠 The TULIP study’s identification of patients with persistent insulin resistance despite weight loss on GLP-1 therapy represents a critical refinement to our understanding of metabolic heterogeneity in this population, challenging the assumption that weight reduction alone predicts glycemic outcomes. This finding underscores that GLP-1 receptor agonists, while potent weight loss agents, do not uniformly improve insulin sensitivity across all patient phenotypes, particularly in those with baseline severe insulin resistance or metabolic dysfunction-associated [fatty liver disease](https://cedclinic.com/cannabinoid-receptor-type-1-antagonist-obesity-steatohepatitis/). Clinicians should implement baseline fasting insulin and HOMA-IR assessment in all patients initiating GLP-1 therapy to risk-stratify for progression to diabetes despite weight loss, enabling earlier consideration of dual or triple therapy approaches such as adding SGLT2 inhibitors or thiazolidinediones for patients demonstrating inadequate metabolic improvement at 12 weeks.

💬 Join the Conversation

Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan)

Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/)

Have thoughts on this? Share it:

[𝕏 Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20New%20Data%20Show%20Subset%20of%20Patients%20at%20Risk%20for%20Diabetes%20Despite%20Weight%20Loss%20%7C%20Drug%20%40drcaplan&url=https%3A%2F%2Fwww.drugtopics.com%2Fview%2Fnew-data-show-subset-of-patients-at-risk-for-diabetes-despite-weight-loss)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fwww.drugtopics.com%2Fview%2Fnew-data-show-subset-of-patients-at-risk-for-diabetes-despite-weight-loss)[🦥 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20New%20Data%20Show%20Subset%20of%20Patients%20at%20Risk%20for%20Diabetes%20Despite%20Weight%20Loss%20%7C%20Drug%20--%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fwww.drugtopics.com%2Fview%2Fnew-data-show-subset-of-patients-at-risk-for-diabetes-despite-weight-loss)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/)

📰 Source: [Google Alert – (“weight loss results” OR “rapid weight loss” OR “appetite suppression” OR “fat loss” OR “metabolic health” OR “insulin resistance”)](https://www.drugtopics.com/view/new-data-show-subset-of-patients-at-risk-for-diabetes-despite-weight-loss)

Nationwide GLP-1 Care
Looking for thoughtful, physician-led GLP-1 guidance?

 CED Clinic offers GLP-1 and metabolic guidance across the United States, including evaluation, prescribing support, side-effect management, and longer-term follow-up for people seeking careful, personalized care.
 

[Learn More](https://cedclinic.com/metabolic/)
[Book Now](https://book.squareup.com/appointments/kn3vehwoiz6to6/location/DPV0VF8Y74WA7/services)

Table of Contents

- [FAQ](#FAQ)[Can I stop worrying about diabetes if I lose weight on GLP-1 medication?](#Can_I_stop_worrying_about_diabetes_if_I_lose_weight_on_GLP-1_medication)
- [What is insulin resistance and why does it matter if I’m taking GLP-1?](#What_is_insulin_resistance_and_why_does_it_matter_if_Im_taking_GLP-1)
- [Will GLP-1 medication fix my insulin resistance?](#Will_GLP-1_medication_fix_my_insulin_resistance)
- [Why did some patients in the TULIP study get worse blood sugar despite weight loss?](#Why_did_some_patients_in_the_TULIP_study_get_worse_blood_sugar_despite_weight_loss)
- [How often should my doctor check my blood sugar while I am on GLP-1?](#How_often_should_my_doctor_check_my_blood_sugar_while_I_am_on_GLP-1)
- [Is there a blood test that shows if I have insulin resistance?](#Is_there_a_blood_test_that_shows_if_I_have_insulin_resistance)
- [If I develop high blood sugar while on GLP-1, does that mean the medication failed?](#If_I_develop_high_blood_sugar_while_on_GLP-1_does_that_mean_the_medication_failed)
- [Can I prevent diabetes if I have insulin resistance while taking GLP-1?](#Can_I_prevent_diabetes_if_I_have_insulin_resistance_while_taking_GLP-1)
- [What does metabolic health mean, and is it different from just losing weight?](#What_does_metabolic_health_mean_and_is_it_different_from_just_losing_weight)
- [Should I get genetic testing if I am on GLP-1 and worried about diabetes risk?](#Should_I_get_genetic_testing_if_I_am_on_GLP-1_and_worried_about_diabetes_risk)
- [Related](#Related)

## FAQ

#### Can I stop worrying about diabetes if I lose weight on GLP-1 medication?

Weight loss is important, but the TULIP study shows that some patients can lose weight and still develop diabetes because of ongoing insulin resistance. Your doctor needs to monitor your blood sugar and insulin levels regularly, not just the number on the scale.

#### What is insulin resistance and why does it matter if I’m taking GLP-1?

Insulin resistance means your body does not respond well to the hormone insulin, which controls blood sugar. Even if you lose weight on GLP-1, if you still have insulin resistance, your blood sugar can get worse over time.

#### Will GLP-1 medication fix my insulin resistance?

GLP-1 medications help with weight loss and can improve blood sugar control, but they do not directly treat all cases of insulin resistance. Your doctor may recommend additional treatments like metformin or lifestyle changes to address insulin resistance.

#### Why did some patients in the TULIP study get worse blood sugar despite weight loss?

The study found that weight loss alone does not guarantee improvement in how your body handles blood sugar. Insulin resistance can continue underneath weight loss, which is why blood sugar monitoring is critical.

#### How often should my doctor check my blood sugar while I am on GLP-1?

You should have blood sugar and insulin tests regularly, typically at baseline and then every 3 to 6 months depending on your risk factors. Your doctor will determine the right schedule based on your individual health status.

#### Is there a blood test that shows if I have insulin resistance?

Yes, your doctor can check fasting insulin levels, glucose levels, and calculate a score called HOMA-IR to measure insulin resistance. These tests help identify whether your insulin resistance is improving even if your weight loss looks good.

#### If I develop high blood sugar while on GLP-1, does that mean the medication failed?

Not necessarily, as some patients can lose weight but still experience worsening blood sugar due to underlying insulin resistance. This finding shows why comprehensive metabolic monitoring matters more than weight alone.

#### Can I prevent diabetes if I have insulin resistance while taking GLP-1?

Yes, GLP-1 combined with other treatments like metformin, healthy eating, and exercise can help prevent or delay diabetes. Regular monitoring allows your doctor to catch problems early and adjust your treatment plan.

#### What does metabolic health mean, and is it different from just losing weight?

Metabolic health includes how well your body handles blood sugar, insulin, cholesterol, and blood pressure overall. Weight loss is one part of metabolic health, but you need all these markers to be healthy to truly prevent disease.

#### Should I get genetic testing if I am on GLP-1 and worried about diabetes risk?

Genetic testing is not routinely needed, but your doctor may recommend it based on your family history and current metabolic markers. Standard blood tests for blood sugar and insulin resistance are the primary tools used to assess your diabetes risk.

[https://cedclinic.com/contact/](https://cedclinic.com/contact/)

Physician-Led, Whole-Person Care
A doctor who takes the time to truly understand you.
Personal care that starts with listening and is guided by experience and ingenuity.

Health, Longevity, Wellness
One-on-One Cannabis Guidance
Metabolic Balance

[Leave a Message](https://cedclinic.com/contact/)
[Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/)
[Medical Consulting](https://cedclinic.com/book/)
[Cannabis Care](https://cedclinic.com/book/)

[https://cedclinic.com/contact/](https://cedclinic.com/contact/)

RELATED READING AT CED CLINIC

Continue exploring the evidence

[GLP-1 Receptor Agonist Weight Loss: Can Genes Predict Results?](https://cedclinic.com/glp-1-pharmacogenomics-weight-loss-genetic-predictors/)

Explore how genetics may influence weight loss outcomes with GLP-1 receptor agonists and implications for personalized treatment.

[Learn More](https://cedclinic.com/glp-1-pharmacogenomics-weight-loss-genetic-predictors/)

[GLP-1 Receptor Agonist Clinical Evidence: Liraglutide vs Semaglutide](https://cedclinic.com/semaglutide-vs-liraglutide-clinical-evidence/)

Compare clinical evidence on liraglutide and semaglutide for weight loss and metabolic effects in diabetes management.

[Read Comparison](https://cedclinic.com/semaglutide-vs-liraglutide-clinical-evidence/)

[GLP-1 Agonist Clinical Evidence: Weight Loss Outcomes](https://cedclinic.com/glp-1-cannabis-use-disorder-bmj-cohort-study/)

Review clinical outcomes of GLP-1 agonists focusing on weight loss and metabolic health improvements.

[Explore Findings](https://cedclinic.com/glp-1-cannabis-use-disorder-bmj-cohort-study/)

 

### Related

---

### Verification & Medical Governance

- **Lead Clinical Author:** Benjamin Caplan, MD
- **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House).
- **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`).
- **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/).
- **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637).
- **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).